WashU IP Startups

Accuronix Therapeutics

Acera Surgical

Advanced Cochlear Diagnostics

AirSeal Cardiovascular, Inc. is pioneering a first-in-class, highly accurate, and accessible blood-based diagnostic to transform the detection and management of peripheral artery disease (PAD), enabling earlier intervention, reducing disability and amputations, and lowering overall healthcare costs.

FacetLab specializes in creating intricate, high-precision patterns on diamond surfaces, enabling breakthrough research in high-pressure science.

LiquidCell Dx was founded by leaders in liquid biopsy, computational biology, AI, and oncology, and is committed to advancing health through innovation, accessibility, and scientific excellence. Using advanced liquid biopsy technology, powerful insights can be extracted from a simple blood sample – opening up new possibilities for understanding health and disease, monitoring treatment response, and personalizing care for patients.

Pixie Bio is developing a next-generation, tumor-targeted therapeutic platform that is modular by design and broadly applicable across solid tumor types- engineered to overcome one of the greatest challenges in immuno-oncology: lack of infiltrating effector cells.

Washington University’s AI-powered breast cancer prediction startup Prognosia has been acquired by Lunit, a leader in AI-based cancer detection technologies. This acquisition aims to accelerate the development and clinical implementation of advanced breast cancer risk assessment tools.